{
    "ticker": "TSVT",
    "name": "Tiziana Life Sciences PLC",
    "description": "Tiziana Life Sciences PLC is a clinical-stage biotechnology company focused on the development of innovative therapies for autoimmune and cancer-related diseases. Established in 2010 and headquartered in London, Tiziana is dedicated to improving patient outcomes through its novel drug candidates. The company is particularly known for its work on therapies that target the endocannabinoid system, which plays a critical role in regulating inflammation and immune responses. Tiziana's leading product candidates include Foralumab, a fully human anti-CD3 monoclonal antibody designed for the treatment of autoimmune diseases, and intranasal delivery formulations that aim to enhance drug bioavailability. With a robust pipeline and a commitment to scientific excellence, Tiziana collaborates with leading academic institutions and industry partners to advance its research. The company is focused on addressing unmet medical needs in indications such as multiple sclerosis, diabetes, and various cancers. Tiziana strives to leverage cutting-edge science to develop therapies that can transform the standard of care for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "London, United Kingdom",
    "founded": "2010",
    "website": "https://www.tizianalifesciences.com",
    "ceo": "Dr. Kunwar Shailubhai",
    "social_media": {
        "twitter": "https://twitter.com/TizianaLife",
        "linkedin": "https://www.linkedin.com/company/tiziana-life-sciences-plc/"
    },
    "investor_relations": "https://www.tizianalifesciences.com/investors",
    "key_executives": [
        {
            "name": "Dr. Kunwar Shailubhai",
            "position": "CEO"
        },
        {
            "name": "Dr. Saurabh Saha",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Foralumab"
            ]
        }
    ],
    "seo": {
        "meta_title": "Tiziana Life Sciences PLC | Innovative Biotechnology Solutions",
        "meta_description": "Tiziana Life Sciences PLC is a clinical-stage biotech company focused on developing therapies for autoimmune and cancer diseases. Explore our innovative solutions and commitment to scientific excellence.",
        "keywords": [
            "Tiziana Life Sciences",
            "Biotechnology",
            "Pharmaceuticals",
            "Foralumab",
            "Autoimmune Diseases",
            "Cancer Treatments"
        ]
    },
    "faq": [
        {
            "question": "What does Tiziana Life Sciences do?",
            "answer": "Tiziana Life Sciences develops innovative therapies for autoimmune conditions and cancer."
        },
        {
            "question": "Who is the CEO of Tiziana Life Sciences?",
            "answer": "Dr. Kunwar Shailubhai is the CEO of Tiziana Life Sciences PLC."
        },
        {
            "question": "Where is Tiziana Life Sciences headquartered?",
            "answer": "Tiziana Life Sciences is headquartered in London, United Kingdom."
        },
        {
            "question": "What are Tiziana's main products?",
            "answer": "Tiziana's main product is Foralumab, aimed at treating autoimmune diseases."
        },
        {
            "question": "When was Tiziana Life Sciences founded?",
            "answer": "Tiziana Life Sciences was founded in 2010."
        }
    ],
    "competitors": [
        "AMGN",
        "BIIB",
        "GILD"
    ],
    "related_stocks": [
        "REGN",
        "VRTX",
        "MRNA",
        "ABBV"
    ]
}